0001) and of hip fracture by 41% (p = 0.002) over 36 months [1]. A subsequent placebo-controlled this website trial (HORIZON-Recurrent Fracture Trial) demonstrated that an annual infusion of ZOL after a recent low-trauma hip fracture significantly reduced the incidence of clinical fractures by 35% (p = 0.001) compared with placebo [2]. The most common adverse events (AEs) associated with ZOL are transient post-dose symptoms (also referred to as an acute phase response) consisting of fever, myalgia, arthralgia, headache, and flu-like symptoms [1]. These symptoms may occur following initial treatment with IV bisphosphonates;
however, the incidence decreases substantially with subsequent treatments [1, 3]. In the HORIZON-Pivotal Fracture Trial, the proportion of patients experiencing any of the five most common post-dose symptoms decreased JAK inhibitor from 32% after the first dose to 7% after the second annual dose and to 3% after the third annual dose [1]. Post-dose symptoms are generally mild to moderate in severity, and most resolve within 3 days, but some may last for 7–14 days [3, 4]. Treatment with analgesics has been reported to mitigate symptoms [3]. The mechanism for the acute
phase response appears to be associated with the transient release of Selleckchem Trichostatin A inflammatory cytokines (e.g., interleukin-6 [IL-6], tumor necrosis factor alpha [TNF-α]) from gamma delta T-cells [5, 6]. Isopentenyl pyrophosphate (IPP) is a known potent activator of gamma delta T-cells [7–9]. ZOL inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase (FPS), a key enzyme in the mevalonate pathway [10, 11]. Blockade of FPS, in turn, results in increased levels of IPP in monocytes [7]. It is believed that the acute phase response following Mirabegron ZOL infusion occurs as a result of IPP-induced T-cell activation and the subsequent release of inflammatory mediators. Statins are commonly used cholesterol-lowering drugs that act by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme
A (HMG-CoA) reductase, a precursor of IPP and cholesterol in the mevalonate pathway. Inhibition of HMG-CoA reductase therefore prevents the synthesis of IPP. In vitro, co-treatment of blood mononuclear cells with a statin and a nitrogen-containing bisphosphonate (N-BP) completely prevents proliferation and activation of gamma delta T-cells caused by N-BPs [12]. We therefore hypothesized that co-administration of a statin with ZOL would have the potential to reduce IPP accumulation in monocytes, prevent proliferation and activation of gamma delta T-cells, and decrease the subsequent acute phase response. ZOL is infused over 15 min and then rapidly binds to bone. Any drug that does not bind to bone is excreted by the kidney within 24 h.